pyrroles has been researched along with Thromboembolism in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Charles-Schoeman, C; Cohen, S; Connell, C; Curtis, JR; Fallon, L; Graham, D; Greenberg, J; Hauben, M; Hung, E; Jones, TV; Kanik, KS; Kremer, J; Madsen, A; Malley, W; Mease, P; Onofrei, A; Valdez, H; Wang, C; Woolcott, J; Yun, H | 1 |
| Hider, SL; Scott, DL; Scott, IC | 1 |
| Fraley, AE; Ganz, P; Kinlay, S; Libby, P; Olsson, AG; Rifai, N; Schwartz, GG; Szarek, M; Tsimikas, S; Witztum, JL | 1 |
| Bellmunt, J; Choueiri, TK; Je, Y; Rosenberg, JE; Schutz, FA | 1 |
| Goldwasser, F; Mir, O; Ropert, S; Vignaux, O | 1 |
| Minor, DR | 1 |
| Berkhof, J; Hoekman, K; Kakkar, AK; Kuenen, BC; Levi, M; Meijers, JC; Pinedo, HM; van Hinsbergh, VW | 1 |
| Kuenen, BC | 1 |
| Hayashi, Y; Inomata, N; Kamei, T; Mizuno, A; Nakanishi, K; Ogata, A; Oka, N; Shibata, M; Shimamoto, T; Takiguchi, C | 1 |
| Cropp, GF; Giaccone, G; Hoekman, K; Huisman, H; Kedde, MA; Kuenen, BC; Levi, M; Noordhuis, P; Parson, MR; Peters, GJ; Pinedo, HM; Rosen, L; Ruijter, R; Scigalla, P; Smit, EF; van der Vijgh, WJ | 1 |
2 review(s) available for pyrroles and Thromboembolism
| Article | Year |
|---|---|
Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials as Topic; Humans; Janus Kinase Inhibitors; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Risk Factors; Sulfonamides; Thromboembolism | 2018 |
Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Arterial Occlusive Diseases; Benzenesulfonates; Humans; Incidence; Indoles; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thromboembolism | 2010 |
3 trial(s) available for pyrroles and Thromboembolism
| Article | Year |
|---|---|
Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardia
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Autoantibodies; Biomarkers; Cholesterol, LDL; Cohort Studies; Female; Heptanoic Acids; Humans; Immunoglobulin G; Immunoglobulin M; Inflammation; Lipoprotein(a); Male; Middle Aged; Oxidation-Reduction; Phospholipids; Pyrroles; Reactive Oxygen Species; Risk Factors; Thromboembolism | 2009 |
Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Cisplatin; Deoxycytidine; E-Selectin; Endothelial Growth Factors; Endothelium, Vascular; Female; Gemcitabine; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Middle Aged; Multivariate Analysis; Platelet Count; Pyrroles; Regression Analysis; Thromboembolism; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Indoles; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Pyrroles; Thromboembolism; Treatment Outcome | 2002 |
5 other study(ies) available for pyrroles and Thromboembolism
| Article | Year |
|---|---|
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Topics: Adult; Aged; Antirheumatic Agents; Clinical Trials as Topic; Female; Humans; Incidence; Male; Middle Aged; Observational Studies as Topic; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rheumatic Diseases; Thromboembolism | 2020 |
VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Indoles; Infarction; Intestines; Male; Plaque, Atherosclerotic; Pyrroles; Risk Factors; Sunitinib; Thromboembolism; Tomography, X-Ray Computed; Vascular Endothelial Growth Factor A | 2011 |
Risk of arterial thrombosis not increased by sorafenib or sunitinib.
Topics: Angiogenesis Inhibitors; Arterial Occlusive Diseases; Benzenesulfonates; Evidence-Based Medicine; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Reproducibility of Results; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thromboembolism | 2010 |
Analysis of prothrombotic mechanisms and endothelial perturbation during treatment with angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Endothelium, Vascular; Humans; Indoles; Neoplasms; Pyrroles; Thromboembolism; Thrombophilia; Treatment Outcome | 2003 |
Synthesis and serotonin 2 (5-HT2) receptor antagonist activity of 5-aminoalkyl-substituted pyrrolo[3,2-c]azepines and related compounds.
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Crystallography, X-Ray; Dogs; Dopamine D2 Receptor Antagonists; Guinea Pigs; Humans; In Vitro Techniques; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Platelet Aggregation Inhibitors; Pyrroles; Rats; Receptors, Adrenergic, beta; Receptors, Dopamine D2; Receptors, Histamine H2; Receptors, Muscarinic; Receptors, Serotonin; Serotonin Antagonists; Spectrophotometry, Infrared; Structure-Activity Relationship; Thromboembolism | 2000 |